Literature DB >> 20110636

Kaposi's sarcoma after long-acting steroids: time until remission and drug washout.

D Nassar1, N E C Schartz, C Bouché, A Lévy, D Kerob, F Agbalika, M Lafaurie, C Lebbé.   

Abstract

Long-acting steroids (LAS) are widely used to treat various inflammatory diseases and allergies. They have many adverse effects including the inhibition of the hypothalamopituitary axis that can last several months. LAS are also strong immunosuppressors and can result in severe opportunistic infections and immunodeficiency-related malignancies. However, the time needed for immune recovery after withdrawal of LAS is unknown. Here we report a case of Kaposi's sarcoma (KS) and severe immunosuppression after a chronic triamcinolone acetonide (TA) treatment. Six months after withdrawal, traces of TA were still detected in the serum by HPLC mass spectrometry. At 8 months, the drug became undetectable, and clinical and biological signs of immune recovery - beginning of KS regression, normalization of IgG levels and CD4 T lymphocyte counts - became noticeable. We then provide a review of the literature on the time until remission of KS after immunosuppression reduction. We also reviewed the cases of KS induced by TA, and the metabolic side effects of TA when compared to standard glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110636     DOI: 10.1159/000277613

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.

Authors:  Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio
Journal:  Intern Emerg Med       Date:  2015-06-23       Impact factor: 3.397

2.  [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus].

Authors:  S Krengel; I Satzger; M Alter; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

3.  A case of exogenous corticosteroid-induced Kaposi's sarcoma that developed after a cure of endogenous hypercortisolism.

Authors:  Soyeon Yoo; Shinhang Moon; Sang-Ouk Chin; Sang-Ah Lee; Changlim Hyun; Gwanpyo Koh
Journal:  Int J Clin Pharm       Date:  2015-08-19

4.  Suspected metastatic adrenocortical carcinoma revealing as pulmonary Kaposi sarcoma in adrenal Cushing's syndrome.

Authors:  Margarita Bala; Cristina L Ronchi; Josef Pichl; Vanessa Wild; Stefan Kircher; Bruno Allolio; Stefanie Hahner
Journal:  BMC Endocr Disord       Date:  2014-07-30       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.